Compounds > prednisone
Page last updated: 2024-11-07

prednisone and Muscular Dystrophy

prednisone has been researched along with Muscular Dystrophy in 54 studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Research Excerpts

ExcerptRelevanceReference
"A recent double-blind, placebo-controlled trial has shown that prednisone improves strength in patients with Duchenne muscular dystrophy."9.07Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group. ( Burrow, KL; Kissel, JT; Mendell, JR; Rammohan, KW, 1991)
"We previously reported the results of a randomized, double-blind 6-month trial of prednisone therapy in which 102 boys aged 5 to 15 years with Duchenne muscular dystrophy received daily doses of 1."9.07A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. ( Brooke, MH; Fenichel, GM; Griggs, RC; King, W; Mendell, JR; Miller, JP; Moxley, RT; Pestronk, A; Robison, J; Signore, L, 1991)
"We performed a randomized, double-blind, controlled six-month trial of prednisone in 103 boys with Duchenne's muscular dystrophy (age, 5 to 15 years)."9.06Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. ( Brooke, MH; Fenichel, GM; Florence, J; Griggs, RC; King, W; Mendell, JR; Miller, JP; Moxley, RT; Pandya, S; Signore, L, 1989)
"We investigated the effect of high-dose prednisone therapy in 33 boys with Duchenne muscular dystrophy."7.67Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. ( Brooke, MH; Fenichel, GM; Florence, JM; Griggs, RC; Kaiser, KK; Mendell, JR; Miller, JP; Moxley, RT; Pandya, S; Signore, L, 1987)
"We report the long-term results of a therapeutic trial of prednisone in the treatment of Duchenne muscular dystrophy, comparing the age at which 16 treated patients and 38 controls lost the ability to ambulate."7.67Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. ( DeSilva, S; Drachman, DB; Kuncl, RW; Mellits, D, 1987)
" The results suggest that (i) DFC and PRED in equal anti-inflammatory dosage are similarly or equally efficient in slowing down the decline of muscle strength in DMD; (ii) benefits outweigh the side effects."6.68Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. ( Reitter, B, 1995)
"The mechanism by which prednisone improves muscle strength and function in Duchenne muscular dystrophy (DMD) is unknown."5.07Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group. ( Bulman, DE; Burghes, AH; Burrow, KL; Coovert, DD; Kissel, JT; Klein, CJ; Mendell, JR; Rammohan, KW, 1991)
"A recent double-blind, placebo-controlled trial has shown that prednisone improves strength in patients with Duchenne muscular dystrophy."5.07Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group. ( Burrow, KL; Kissel, JT; Mendell, JR; Rammohan, KW, 1991)
"We previously reported the results of a randomized, double-blind 6-month trial of prednisone therapy in which 102 boys aged 5 to 15 years with Duchenne muscular dystrophy received daily doses of 1."5.07A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. ( Brooke, MH; Fenichel, GM; Griggs, RC; King, W; Mendell, JR; Miller, JP; Moxley, RT; Pestronk, A; Robison, J; Signore, L, 1991)
"We performed a randomized, double-blind, controlled six-month trial of prednisone in 103 boys with Duchenne's muscular dystrophy (age, 5 to 15 years)."5.06Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. ( Brooke, MH; Fenichel, GM; Florence, J; Griggs, RC; King, W; Mendell, JR; Miller, JP; Moxley, RT; Pandya, S; Signore, L, 1989)
"Three months of intermittent prednisone therapy could improve cardiac and skeletal muscle function in congenital muscular dystrophy."3.80Short-term effects of corticosteroid therapy on cardiac and skeletal muscles in muscular dystrophies. ( Fawaz, L; Ghafar, HA; Hussein, G; Mansour, L; Mostafa, FA, 2014)
"We investigated the effect of high-dose prednisone therapy in 33 boys with Duchenne muscular dystrophy."3.67Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. ( Brooke, MH; Fenichel, GM; Florence, JM; Griggs, RC; Kaiser, KK; Mendell, JR; Miller, JP; Moxley, RT; Pandya, S; Signore, L, 1987)
"We report the long-term results of a therapeutic trial of prednisone in the treatment of Duchenne muscular dystrophy, comparing the age at which 16 treated patients and 38 controls lost the ability to ambulate."3.67Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. ( DeSilva, S; Drachman, DB; Kuncl, RW; Mellits, D, 1987)
" Although most children with dermatomyositis have a good prognosis, the best predictor of both good functional recovery and minimal calcinosis is early treatment after the onset of symptoms, using high doses of prednisone for an adequate length of time."3.66Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. ( Blane, CE; Bowyer, SL; Cassidy, JT; Sullivan, DB, 1983)
" The results suggest that (i) DFC and PRED in equal anti-inflammatory dosage are similarly or equally efficient in slowing down the decline of muscle strength in DMD; (ii) benefits outweigh the side effects."2.68Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. ( Reitter, B, 1995)
"Prednisone has been shown to improve strength in Duchenne dystrophy."2.67Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months) ( Brooke, MH; Cwik, VA; Fenichel, GM; Griggs, RC; Mendell, JR; Miller, JP; Moxley, RT; Pandya, S; Pestronk, A; Robison, J, 1993)
"Boys treated with prednisone had stronger average muscle strength scores, than did boys treated with placebo as early as 10 days after starting therapy."2.67Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. ( Brooke, MH; Fenichel, GM; Griggs, RC; Mendell, JR; Miller, JP; Moxley, RT; Pestronk, A, 1991)
"The most common myopathy in children, Duchenne muscular dystrophy (DMD), is the focus of active pharmacologic clinical trials."2.41Pharmacologic and genetic therapy for childhood muscular dystrophies. ( Escolar, DM; Scacheri, CG, 2001)
"Prednisone therapy was associated with: (i) functional improvement of overall motor disability, in upper limbs of DMD (P < 0."1.33The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies. ( Abu-Dief, EE; Hamed, SA; Hussein, MR; Kamel, NF; Kandil, MR; Mostafa, MG, 2006)
"On treatment with prednisone, the patient's strength and reading skill improved, symptoms resolved, and muscle enzymes returned to normal."1.26Reversible alexia, mitochondrial myopathy, and lactic acidemia. ( Skoglund, RR, 1979)

Research

Studies (54)

TimeframeStudies, this research(%)All Research%
pre-199028 (51.85)18.7374
1990's19 (35.19)18.2507
2000's3 (5.56)29.6817
2010's4 (7.41)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cramer, ML1
Shao, G1
Rodino-Klapac, LR1
Chicoine, LG1
Martin, PT1
Politano, L1
Scutifero, M1
Patalano, M1
Sagliocchi, A1
Zaccaro, A1
Civati, F1
Brighina, E1
Vita, G2
Messina, S1
Sframeli, M1
Lombardo, ME1
Scalise, R1
Colia, G1
Catteruccia, M1
Berardinelli, A1
Motta, MC1
Gaiani, A1
Semplicini, C1
Bello, L1
Astrea, G1
Ricci, G1
D'Angelo, MG1
Pane, M1
D'Amico, A1
Balottin, U1
Angelini, C1
Battini, R1
Magliano, L1
Hussein, G1
Mansour, L1
Ghafar, HA1
Mostafa, FA1
Fawaz, L1
Hussein, MR2
Abu-Dief, EE2
Kamel, NF2
Mostafa, MG2
WALTON, JN3
FOWLER, WM1
PEARSON, CM1
De Luca, A1
Hamed, SA1
Kandil, MR1
Foidart, M1
Liem, HH1
Adornato, BT1
Engel, WK1
Muller-Eberhard, U1
Bowyer, SL1
Blane, CE1
Sullivan, DB1
Cassidy, JT1
Thompson, CE1
Mateos, F1
Higuchi, I1
Nakamura, K1
Nakagawa, M1
Nakamura, N1
Usuki, F1
Inose, M1
Osame, M1
Rifai, Z1
Welle, S1
Moxley, RT9
Lorenson, M1
Griggs, RC9
Mendell, JR11
Fenichel, GM6
Brooke, MH7
Pestronk, A5
Miller, JP6
Cwik, VA2
Pandya, S4
Robison, J3
Kissel, JT3
Lynn, DJ1
Rammohan, KW3
Klein, JP1
Jennekens, FG1
de Visser, M1
Wintzen, AR1
Wokke, JH1
Reitter, B1
Tawil, R1
McDermott, MP1
King, W4
Kissel, J1
Stern, LM1
Tomas, FM1
Burgoyne, J1
Connolly, AM1
Mehta, S1
Al-Lozi, M1
Escolar, DM1
Scacheri, CG1
Munsat, TL2
Cohen, L1
Morgan, J1
Bozyk, ME1
Jerusalem, F1
Skoglund, RR1
Somer, H1
Florence, JM2
Burrow, KL2
Coovert, DD1
Klein, CJ1
Bulman, DE1
Burghes, AH1
Dubowitz, V1
Bazan, JA1
Signore, L3
Florence, J1
Brown, RH1
Oexle, K1
Kingston, WJ1
Kaiser, KK1
DeSilva, S1
Drachman, DB2
Mellits, D1
Kuncl, RW1
Toyka, KV1
Myer, E1
Richier, JL1
Guérin, D1
Leblay, R1
Pony, JC1
Gross, S1
Maskaleris, ML1
Haas, DC1
Arnason, BG1
Piper, D1
Cancilla, P1
Mednick, J1
Rothstein, TL1
Carlson, CB1
Sumi, SM1
Burckhardt, D1
LaDue, JS1
Allen, DT1
Saunders, AM1
Northway, WH1
Williams, GF1
Schafer, IA1
Kibrick, AC2
Power, HL1
Sevendal, E1
Milhorat, AT2
Fitch, CD1
Lucy, DD1
Bornhofen, JH1
Dalrymple, GV1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen[NCT01603407]Phase 3196 participants (Actual)Interventional2013-01-31Completed
Phase I/IIa Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2[NCT03333590]Phase 1/Phase 22 participants (Actual)Interventional2017-11-06Active, not recruiting
Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321]100 participants (Anticipated)Observational2014-01-31Active, not recruiting
Low-level Mechanical Vibration, Bone Density, Bone Resorption and Muscular Strength in Ambulant Children Affected by Duchenne Muscular Dystrophy[NCT05281120]20 participants (Actual)Interventional2006-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

6 Minute Walk Test

Measures the total distance walked in 6 minutes averaged over all post-baseline follow-up visits through Month 36. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventionmeters (Least Squares Mean)
Daily Prednisone384.95
Daily Deflazacort384.17
Intermittent Prednisone346.81

Forced Vital Capacity

Forced vital capacity was measured during a spirometry test. Forced expiratory volume (FEV) measures how much air a person can exhale during a forced breath. Forced vital capacity (FVC) is the total amount of air exhaled during the FEV test. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventionliters (Least Squares Mean)
Daily Prednisone1.4
Daily Deflazacort1.4
Intermittent Prednisone1.5

Fractional Shortening Percent

Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months

Interventionpercentage of fractional shortening (Least Squares Mean)
Daily Prednisone33.74
Daily Deflazacort34.01
Intermittent Prednisone34.33

Heart Rate

Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months

Interventionbpm (Least Squares Mean)
Daily Prednisone94.10
Daily Deflazacort93.52
Intermittent Prednisone91.65

Left Ventricular Ejection Fraction Percent

Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months

Interventionpercentage of ejection fraction (Least Squares Mean)
Daily Prednisone61.88
Daily Deflazacort62.65
Intermittent Prednisone62.45

North Star Ambulatory Assessment (NSAA) Score

"The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy (DMD). It is usually used to monitor the progression of the disease and treatment effects.~The activities are graded as follows:~2 - Normal - no obvious modification of activity~1 - Modified method but achieves goal independent of physical assistance from another 0 - Unable to achieve independently This scale is ordinal with 34 as the maximum score indicating fully-independent function." (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventionscore on a scale (Least Squares Mean)
Daily Prednisone23.7
Daily Deflazacort24.0
Intermittent Prednisone20.7

Number of Participants Who Tolerated the Regimen

The number of participants who completed 36 months of follow-up on the originally assigned dosage (for weight) of study medication. (NCT01603407)
Timeframe: 3 years

InterventionParticipants (Count of Participants)
Daily Prednisone36
Daily Deflazacort36
Intermittent Prednisone37

Participant Body Mass Index

(NCT01603407)
Timeframe: 36 months

Interventionkilograms/square meter (Least Squares Mean)
Daily Prednisone18.9
Daily Deflazacort18.3
Intermittent Prednisone18.1

Participant Height

(NCT01603407)
Timeframe: 36 months

Interventioncentimeters (Least Squares Mean)
Daily Prednisone116.8
Daily Deflazacort115.3
Intermittent Prednisone119.9

Participant Weight

(NCT01603407)
Timeframe: 36 months

Interventionkilograms (Least Squares Mean)
Daily Prednisone26.3
Daily Deflazacort24.9
Intermittent Prednisone26.3

PR Interval

Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months

Interventionmilliseconds (Least Squares Mean)
Daily Prednisone115.59
Daily Deflazacort116.87
Intermittent Prednisone117.90

Quality of Life - Parent

Quality of life was measured by parent/guardian self-report for all children utilizing the PEDSQL measurement tool. This is a 23-question tool. Scores can range from 0 to 100, with higher scores indicating better quality of life for the child. (NCT01603407)
Timeframe: Average of Months 12, 24, and 36 visits

Interventionscore on a scale (Least Squares Mean)
Daily Prednisone64.88
Daily Deflazacort63.71
Intermittent Prednisone61.33

Quality of Life- Child

Quality of life was measured by child self-report in children age 5 and older utilizing the PEDSQL measurement tool. This is a 23-question tool. Scores can range from 0 to 100, with higher scores indicating better quality of life. (NCT01603407)
Timeframe: Average of Months 12, 24, and 36 visits

Interventionscore on a scale (Least Squares Mean)
Daily Prednisone67.39
Daily Deflazacort64.96
Intermittent Prednisone65.07

Range of Motion (Goniometry) of Left Ankle

Range of motion at the ankle joint in dorsiflexion measured in degrees from plantigrade averaged over all post-baseline visits. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventiondegrees (Mean)
Daily Prednisone4.39
Daily Deflazacort3.29
Intermittent Prednisone2.67

Range of Motion (Goniometry) of Right Ankle

Range of motion at the ankle joint in dorsiflexion measured in degrees from plantigrade averaged over all post-baseline visits. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventiondegrees (Mean)
Daily Prednisone4.05
Daily Deflazacort2.81
Intermittent Prednisone2.29

Rise From the Floor Velocity

Reciprocal of time to rise from the floor (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventionrise/sec (Least Squares Mean)
Daily Prednisone0.24
Daily Deflazacort0.24
Intermittent Prednisone0.18

Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction With Treatment Score

The TSQM Global Satisfaction with Treatment is a 14-item questionnaire that ranges from 0 - 100 with higher scores indicating better outcomes. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Interventionscore on a scale (Least Squares Mean)
Daily Prednisone71.2
Daily Deflazacort67.8
Intermittent Prednisone65.1

Expression of GALGT2 as Demonstrated by Immunofluorescent Staining With Anti-CT Epitope Antibodies or WFA Lectin in Muscle Biopsy Sections at 120 Days Post Injection (Cohort 1) and 90 Days Post-injection (Cohort 2).

Percentage of fibers expressing GALGT2 in each biopsy sample. (NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1)

InterventionPercentage of Positive Fibers (Number)
Cohort 1 (Minimal Efficacious Dose)1.95
Cohort 21.72

GALGT2 Protein Expression Quantified by Western Blot and Assessed by Densitometry in Muscle Biopsy Tissue at 120 Days Post-injection (Cohort 1) and 90 Days Post-injection (Cohort 2)

(NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1)

Interventionng/mg total protein (Number)
Cohort 1 (Minimal Efficacious Dose)12
Cohort 214.6

Number of Unanticipated Grade III or Higher Treatment-Related Toxicities

(NCT03333590)
Timeframe: 2 years

Interventionevents (Number)
Cohort 1 (Minimal Efficacious Dose)0
Cohort 20

Number of Meters Walked During the 6 Minute Walk Test

(NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1) and Day 180 for both cohorts

,
Interventionmeters (Number)
Day 90 (Cohort 2) /Day 120 (Cohort 1)Day 180
Cohort 1 (Minimal Efficacious Dose)320324
Cohort 2 (Minimal Efficacious Dose)405416

Score of Muscle Function Using the The North Star Ambulatory Assessment (NSAA).

The NSAA provides a score between 0 and 34 where higher numbers represent greater muscle function. (NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1) and both Cohorts at Day 180, Months 12, 18 and 24

,
Interventionscore on a scale (Number)
Day 90/Day 120Day 180Month 12Month 18Month 24
Cohort 1 (Minimal Efficacious Dose)16141062
Cohort 22123232323

Strength of the Bilateral Knee Flexors and Extensors During the Maximal Voluntary Isometric Strength Test.

(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1) and both Cohorts at Day 180, Months 12, 18 and 24

,
Interventionkg (Number)
Day 90/Day 120-Right Knee ExtensionDay 90/Day 120-Right Knee FlexionDay 90/Day 120- Left Knee ExtensionDay 90/Day 120-Left Knee FlexionDay 180-Right Knee ExtensionDay 180-Right Knee FlexionDay 180-Left Knee ExtensionDay 180-Left Knee FlexionMonth 12-Right Knee ExtensionMonth 12-Right Knee FlexionMonth 12-Left Knee ExtensionMonth 12-Left Knee FlexionMonth 18-Right Knee ExtensionMonth 18-Right Knee FlexionMonth 18-Left Knee ExtensionMonth 18-Left Knee FlexionMonth 24-Right Knee ExtensionMonth 24-Right Knee FlexionMonth 24-Left Knee ExtensionMonth 24-Left Knee Flexion
Cohort 1 (Minimal Efficacious Dose)7.426.068.786.127.136.18.666.697.495.677.55.324.556.114.966.265.064.416.934.17
Cohort 27.048.125.98.49.734.248.195.259.855.858.025.127.676.897.346.089.815.045.214.87

Time Taken to Walk 100 Meters During the 100 Meter Walk Test.

(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1); both Cohorts at Day 180, Months 12, 18 and Cohort 2 at Month 24

Interventionseconds (Number)
Day 90/Day 120Day 180Month 12Month 18
Cohort 1 (Minimal Efficacious Dose)98.2110.9144.5167.8

Time Taken to Walk 100 Meters During the 100 Meter Walk Test.

(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1); both Cohorts at Day 180, Months 12, 18 and Cohort 2 at Month 24

Interventionseconds (Number)
Day 90/Day 120Day 180Month 12Month 18Month 24
Cohort 256.144.944.765.648.4

Reviews

9 reviews available for prednisone and Muscular Dystrophy

ArticleYear
SOME DISEASES OF MUSCLE.
    Lancet (London, England), 1964, Feb-29, Volume: 1, Issue:7331

    Topics: Betamethasone; Cushing Syndrome; Dexamethasone; Diagnosis; Humans; Muscular Diseases; Muscular Dystr

1964
[Duchenne muscular dystrophy: clinical analysis and prospects of genetic therapy].
    Revista de neurologia, 1995, Volume: 23 Suppl 3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Genetic Therapy; Humans; Muscular Dystrophies; Prednisone;

1995
[For the present Duchenne' disease should not be treated with prednisone].
    Nederlands tijdschrift voor geneeskunde, 1996, May-25, Volume: 140, Issue:21

    Topics: Anti-Inflammatory Agents; Child; Humans; Male; Muscular Dystrophies; Prednisone

1996
Pharmacologic and genetic therapy for childhood muscular dystrophies.
    Current neurology and neuroscience reports, 2001, Volume: 1, Issue:2

    Topics: Animals; Cell Transplantation; Child; Child, Preschool; Clinical Trials as Topic; Creatine; Cytoskel

2001
[Treatment of myopathies and spinal muscular atrophies (author's transl)].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1978, Jan-24, Volume: 67, Issue:4

    Topics: Amyotrophic Lateral Sclerosis; Azathioprine; Collagen Diseases; Dermatomyositis; Glycogen Storage Di

1978
[Can muscular dystrophy be treated?].
    Duodecim; laaketieteellinen aikakauskirja, 1992, Volume: 108, Issue:6

    Topics: Animals; Child; Humans; Male; Mice; Mice, Inbred mdx; Muscles; Muscular Dystrophies; Prednisone; Ste

1992
Prednisone in Duchenne dystrophy.
    Neuromuscular disorders : NMD, 1991, Volume: 1, Issue:3

    Topics: Adolescent; Child; Child, Preschool; Female; Humans; Male; Muscular Dystrophies; Prednisone

1991
Immunosuppressive therapy in Duchenne muscular dystrophy: considerations for myoblast transfer studies.
    Advances in experimental medicine and biology, 1990, Volume: 280

    Topics: Adolescent; Child; Child, Preschool; Combined Modality Therapy; HLA Antigens; Humans; Immunosuppress

1990
Treatment of muscular dystrophies and inflammatory myopathies.
    Clinical neuropharmacology, 1986, Volume: 9, Issue:4

    Topics: Azathioprine; Clinical Trials as Topic; Dermatomyositis; Humans; Muscular Dystrophies; Myositis; Myo

1986

Trials

15 trials available for prednisone and Muscular Dystrophy

ArticleYear
Steroid therapy is associated with decreased numbers of dendritic cells and fibroblasts, and increased numbers of satellite cells, in the dystrophic skeletal muscle.
    Journal of clinical pathology, 2010, Volume: 63, Issue:9

    Topics: Adolescent; Biopsy; Cell Count; Child; Child, Preschool; Dendritic Cells; Fibroblasts; Glucocorticoi

2010
Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months)
    Neurology, 1993, Volume: 43, Issue:3 Pt 1

    Topics: Adolescent; Azathioprine; Body Height; Child; Child, Preschool; Double-Blind Method; Drug Therapy, C

1993
Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy.
    Neurology, 1993, Volume: 43, Issue:3 Pt 1

    Topics: Adolescent; Antigens, CD; Azathioprine; B-Lymphocytes; Child; Child, Preschool; Drug Therapy, Combin

1993
Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study.
    Brain & development, 1995, Volume: 17 Suppl

    Topics: Alkaline Phosphatase; Anti-Inflammatory Agents; Body Weight; Child; Child, Preschool; Creatine Kinas

1995
Letter: Prednisone in Duchenne muscular dystrophy.
    Lancet (London, England), 1975, Feb-01, Volume: 1, Issue:7901

    Topics: Child; Child, Preschool; Clinical Trials as Topic; Drug Evaluation; Follow-Up Studies; Humans; Muscu

1975
Letter: Prednisone in Duchenne muscular dystrophy.
    Lancet (London, England), 1975, Feb-15, Volume: 1, Issue:7903

    Topics: Child, Preschool; Clinical Trials as Topic; Drug Evaluation; Humans; Male; Muscular Dystrophies; Pal

1975
Long-term benefit from prednisone therapy in Duchenne muscular dystrophy.
    Neurology, 1991, Volume: 41, Issue:12

    Topics: Adolescent; Child; Child, Preschool; Double-Blind Method; Humans; Male; Muscles; Muscular Dystrophie

1991
Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group.
    Neurology, 1991, Volume: 41, Issue:5

    Topics: Adolescent; Child; Child, Preschool; Chromosome Deletion; Dose-Response Relationship, Drug; Double-B

1991
Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group.
    Archives of neurology, 1991, Volume: 48, Issue:4

    Topics: Adolescent; Analysis of Variance; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-

1991
Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group.
    Archives of neurology, 1991, Volume: 48, Issue:4

    Topics: Adolescent; Analysis of Variance; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-

1991
Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group.
    Archives of neurology, 1991, Volume: 48, Issue:4

    Topics: Adolescent; Analysis of Variance; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-

1991
Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group.
    Archives of neurology, 1991, Volume: 48, Issue:4

    Topics: Adolescent; Analysis of Variance; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-

1991
Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group.
    Neurology, 1991, Volume: 41, Issue:5

    Topics: Adolescent; Antigens, Surface; Child; Child, Preschool; Double-Blind Method; Humans; Monocytes; Musc

1991
A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy.
    Archives of neurology, 1991, Volume: 48, Issue:6

    Topics: Adolescent; Body Weight; Child; Child, Preschool; Double-Blind Method; Drug Administration Schedule;

1991
Immunosuppressive therapy in Duchenne muscular dystrophy: considerations for myoblast transfer studies.
    Advances in experimental medicine and biology, 1990, Volume: 280

    Topics: Adolescent; Child; Child, Preschool; Combined Modality Therapy; HLA Antigens; Humans; Immunosuppress

1990
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Mu

1989
Treatment of muscular dystrophies and inflammatory myopathies.
    Clinical neuropharmacology, 1986, Volume: 9, Issue:4

    Topics: Azathioprine; Clinical Trials as Topic; Dermatomyositis; Humans; Muscular Dystrophies; Myositis; Myo

1986
Prednisone in Duchenne muscular dystrophy.
    Lancet (London, England), 1974, Dec-14, Volume: 2, Issue:7894

    Topics: Activities of Daily Living; Blood Cell Count; Body Weight; Child; Child Health Services; Child, Pres

1974

Other Studies

32 other studies available for prednisone and Muscular Dystrophy

ArticleYear
Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone.
    Human gene therapy, 2017, Volume: 28, Issue:6

    Topics: Administration, Oral; Animals; Capsid Proteins; CD8-Positive T-Lymphocytes; Cell Death; Dependovirus

2017
Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventions.
    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology, 2017, Volume: 36, Issue:1

    Topics: Adolescent; Age Factors; Bone Density Conservation Agents; Breathing Exercises; Cardiotonic Agents;

2017
Short-term effects of corticosteroid therapy on cardiac and skeletal muscles in muscular dystrophies.
    Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2014, Volume: 62, Issue:6

    Topics: Adolescent; Child; Child, Preschool; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Muscl

2014
DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF SERUM ENZYMES. II. NEUROLOGIC DISEASES OTHER THAN MUSCULAR DYSTROPHY.
    Archives of physical medicine and rehabilitation, 1964, Volume: 45

    Topics: Adenosine Triphosphatases; Alanine Transaminase; Arthritis; Arthritis, Rheumatoid; Aspartate Aminotr

1964
Prednisone in dystrophin-deficient Caernorabditis elegans.
    Neuromuscular disorders : NMD, 2004, Volume: 14, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Caenorhabditis elegans; Disease Models, Animal; Dystrophin; Muscu

2004
The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.
    International journal of experimental pathology, 2006, Volume: 87, Issue:6

    Topics: Adolescent; Adult; Analysis of Variance; Biopsy; Child; Child, Preschool; Dendritic Cells; Female; G

2006
Hemopexin metabolism in patients with altered serum levels.
    The Journal of laboratory and clinical medicine, 1983, Volume: 102, Issue:5

    Topics: Adolescent; Adult; Aged; Azathioprine; Creatine Kinase; Female; Hemopexin; Humans; Male; Middle Aged

1983
Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification.
    The Journal of pediatrics, 1983, Volume: 103, Issue:6

    Topics: Adolescent; Calcinosis; Child; Child, Preschool; Dermatomyositis; Female; Humans; Infant; Male; Musc

1983
Infantile Myositis.
    Developmental medicine and child neurology, 1982, Volume: 24, Issue:3

    Topics: Creatine Kinase; Diagnosis, Differential; Female; Humans; Infant; Male; Muscles; Muscular Dystrophie

1982
Steroid-responsive myalgia in a patient with Becker muscular dystrophy.
    Journal of the neurological sciences, 1993, Volume: 115, Issue:2

    Topics: Adult; Antibodies, Monoclonal; Histocytochemistry; Humans; Immunohistochemistry; Male; Muscles; Musc

1993
Effect of prednisone on protein metabolism in Duchenne dystrophy.
    The American journal of physiology, 1995, Volume: 268, Issue:1 Pt 1

    Topics: Adult; Body Weight; Child; Child, Preschool; Hormones; Humans; Muscle Proteins; Muscles; Muscular Dy

1995
A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group.
    Neurology, 1997, Volume: 48, Issue:1

    Topics: Adolescent; Adult; Arm; Face; Female; Humans; Male; Middle Aged; Muscles; Muscular Dystrophies; Pilo

1997
Monitoring the effects of prednisone in Duchenne dystrophy.
    Journal of paediatrics and child health, 1996, Volume: 32, Issue:2

    Topics: Anti-Inflammatory Agents; Child; Creatinine; Drug Administration Schedule; Drug Monitoring; Humans;

1996
Primary alpha-sarcoglycan deficiency responsive to immunosuppression over three years.
    Muscle & nerve, 1998, Volume: 21, Issue:11

    Topics: Amino Acid Substitution; Anti-Inflammatory Agents; Antibodies; Biopsy; Child; Cytoskeletal Proteins;

1998
Variable effects of corticosteroid treatment of serum enzyme activities in Duchenne's muscular dystrophy.
    Research communications in chemical pathology and pharmacology, 1977, Volume: 17, Issue:3

    Topics: Adolescent; Alkaline Phosphatase; Child; Creatine Kinase; Glucocorticoids; Humans; L-Lactate Dehydro

1977
Reversible alexia, mitochondrial myopathy, and lactic acidemia.
    Neurology, 1979, Volume: 29, Issue:5

    Topics: Child; Dyslexia, Acquired; Electromyography; Enzymes; Humans; Lactates; Liver; Male; Mitochondria, M

1979
Steroids and muscular dystrophy.
    Neurology, 1991, Volume: 41, Issue:10

    Topics: Humans; Muscular Dystrophies; Prednisone

1991
Prednisone therapy for Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Jun-15, Volume: 320, Issue:24

    Topics: Humans; Muscles; Muscular Dystrophies; Prednisone

1989
Prednisone therapy for Duchenne's muscular dystrophy.
    The New England journal of medicine, 1989, Nov-23, Volume: 321, Issue:21

    Topics: Humans; Muscles; Muscular Dystrophies; Prednisone

1989
Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone.
    Archives of neurology, 1987, Volume: 44, Issue:8

    Topics: Adolescent; Child; Child, Preschool; Contracture; Drug Evaluation; Electromyography; Humans; Male; M

1987
Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit.
    Archives of neurology, 1987, Volume: 44, Issue:8

    Topics: Adolescent; Body Weight; Child; Child, Preschool; Follow-Up Studies; Humans; Locomotion; Male; Muscu

1987
[Therapeutic effect of alpha-tocopher- yl-quinone on muscular disorders of hyperthyroidism and of prolonged treatment by corticoids and antimitotics].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1969, Apr-26, Volume: 45, Issue:20

    Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Asthenia; Busulfan; Chlorambucil; Cobal

1969
Letter: Dermatomyositis: urinary chromatographic findings by alkaline autoanalysis for peptides (one case).
    Clinical chemistry, 1973, Volume: 19, Issue:12

    Topics: Adolescent; Autoanalysis; Chromatography, Ion Exchange; Dermatomyositis; Female; Humans; Male; Metho

1973
Cell-mediated immunity in polymyositis. Creatine phosphokinase release from muscle cultures.
    Archives of neurology, 1974, Volume: 31, Issue:3

    Topics: Adolescent; Adult; Aged; Autoimmune Diseases; Azathioprine; Child; Creatine Kinase; Culture Techniqu

1974
Inflammatory myopathy with facioscapulohumeral distribution.
    Neurology, 1972, Volume: 22, Issue:4

    Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; Child; Creatine; Creatine Kina

1972
Polymyositis with facioscapulohumeral distribution.
    Archives of neurology, 1971, Volume: 25, Issue:4

    Topics: Child; Creatine Kinase; Dermatomyositis; Electromyography; Enzymes; Facial Muscles; Female; Humans;

1971
Enzyme changes following prednisone-induced remission in progressive muscular dystrophy.
    New York state journal of medicine, 1967, Feb-15, Volume: 67, Issue:4

    Topics: Aspartate Aminotransferases; Creatine Kinase; Humans; Hydroxybutyrate Dehydrogenase; Male; Middle Ag

1967
Corticosteroids in the treatment of Engelmann's disease: progressive diaphyseal dysplasia.
    Pediatrics, 1970, Volume: 46, Issue:4

    Topics: Bone Resorption; Child, Preschool; Cortisone; Exostoses; Female; Femur; Fibula; Gait; Growth; Havers

1970
Prednisone effect on urinary excretion of hydroxyproline in patients with muscular dystrophy.
    The Journal of clinical endocrinology and metabolism, 1968, Volume: 28, Issue:8

    Topics: Adolescent; Adult; Chemistry, Clinical; Child; Collagen; Humans; Hydroxyproline; Male; Muscular Dyst

1968
Creatine metabolism in skeletal muscle. II. creatine kinetics in man.
    Neurology, 1968, Volume: 18, Issue:1 Pt 1

    Topics: Adult; Carbon Isotopes; Child; Child, Preschool; Creatine; Creatinine; Female; Humans; Kinetics; Mal

1968
Muscular dystrophies and their management.
    British medical journal, 1969, Sep-13, Volume: 3, Issue:5671

    Topics: Adolescent; Adult; Child; Child, Preschool; Female; Humans; Male; Muscular Dystrophies; Myotonia; Ph

1969
Prednisone effect on serum hydroxyproline fractions.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1969, Volume: 131, Issue:4

    Topics: Adolescent; Adult; Animals; Blood Proteins; Child; Depression, Chemical; Diffusion; Humans; Hydroxyp

1969